All In Biotech

NDA 208144 · Bausch and Lomb INC

Lumify

Brimonidine Tartrate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Dec 22, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

177

44 Phase 3, 5 recruiting

FAERS reports

3,396

1,716 serious, 189 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 31, 2026.

Use relieves redness of the eye due to minor eye irritations

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 22, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • LUMIFY · BRIMONIDINE TARTRATE 0.025% · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Brimonidine" as an intervention, any sponsor and status, largest first.

All 177 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain288
  • eye irritation218
  • product use issue194
  • fatigue185
  • drug ineffective180
  • headache169
  • ocular hyperaemia164
  • vision blurred164
  • dizziness146
  • product dose omission issue127
  • death119
  • off label use116

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200428
200539
200636
200753
200837
200945
201055
201181
201277
201344
201452
201593
2016109
2017112
2018146
2019159
2020275
2021213
2022245
2023291
2024323
2025376
2026507

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 313 on PubMed

Sponsor: Bausch and Lomb INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.